AIHTA - Publications - Search - Year: 2020
Number of items: 18.

Wild, C. and Sehic, O. (2020): Proton and carbon ion therapy - an update on indications. AIHTA Policy Brief 004.

Grössmann, N. (2020): Entrectinib (Rozlytrek®) for the treatment of patients whose solid tumours have a NTRK gene fusion, or patients with ROS1-positive advanced NSCLC. Oncology Fact Sheet Nr. 13.

Grössmann, N. (2020): Alpelisib (Piqray®) plus fulvestrant for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. Oncology Fact Sheet Nr. 12.

Grössmann, N. (2020): Maintenance olaparib (Lynparza®) for the treatment of patients with germline BRCA-mutated metastatic pancreatic cancer. Oncology Fact Sheet Nr. 11.

Grössmann, N. (2020): Glasdegib (Daurismo®) with low-dose cytarabine (LDAC) in patients with newly diagnosed acute myeloid leukaemia (AML). Oncology Fact Sheet Nr. 10.

Grössmann, N. (2020): Daratumumab (Darzalex®) in a new pharmaceutical form associated with a new strength and a new route of administration for the treatment of multiple myeloma. Oncology Fact Sheet Nr. 9.

Wild, C and Wolf, S and Goetz, G and Walter, M and McEntee, J and Stanak, M and Ettinger, S and Strohmaier, C and Erdos, J and Huic, M. (2020): Covid-19: HSS/ Horizon Scanning Living Document. AIHTA Policy Brief 002.

Grössmann, N. (2020): Encorafenib (Braftovi®) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. Oncology Fact Sheet Nr. 7.

Grössmann, N. (2020): Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel containing regimen. Oncology Fact Sheet Nr. 8.

Grössmann, N (2020): Brentuximab vedotin (Adcetris®) with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCL). Oncology Fact Sheet Nr. 5.

Wild, C. (2020): Update 12 months follow-up: Nusinersen in spinal muscular atrophy ("late onset") in children and adolescents ≥ 6 years. AIHTA Policy Brief 001.

Grössmann, N (2020): Isatuximab (Sarclisa®) plus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (MM). Oncology Fact Sheet Nr. 6.

Robausch, M and Grössmann, N (2020): Health Services Research in Oncology. Part I: End-of-Life Care . HTA-Projektbericht 127.

Grössmann, N. (2020): Brigatinib (Alunbrig®) in ALK-positive non–small-cell lung cancer (NSCLC). Oncology Fact Sheet Nr. 4.

Wild, C. and Blagojevic, S. (2020): Jahresbericht 2019.

Grössmann, N. (2020): Rituximab (MabThera®) for the treatment of paediatric patients with previously untreated advanced stage CD20 positive DLBCL, BL, BAL, or BLL. Oncology Fact Sheet Nr. 3.

Grössmann, N. (2020): Venetoclax (Venclyxto®) and obinutuzumab in patients with chronic lymphocytic leukaemia (CLL) and coexisting conditions. Oncology Fact Sheet Nr. 1.

Grössmann, N. (2020): Darolutamide (Nubeqa®) in nonmetastatic, castration-resistant prostate cancer (nmCRPC). Oncology Fact Sheet Nr. 2.

This list was generated on Tue Jul 7 05:00:03 2020 CEST.